Lonza Group AG
SIX:LONN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
343.4
587.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Lonza Group AG
Lonza Group AG
Operating Income
Lonza Group AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lonza Group AG
SIX:LONN
|
Operating Income
CHf874m
|
CAGR 3-Years
13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
9%
|
|
|
Bachem Holding AG
SIX:BANB
|
Operating Income
CHf130m
|
CAGR 3-Years
3%
|
CAGR 5-Years
16%
|
CAGR 10-Years
15%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Operating Income
CHf177.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Tecan Group AG
SIX:TECN
|
Operating Income
CHf98.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Operating Income
-€33.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Operating Income
CHf37.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Lonza Group AG
Glance View
Amidst the serene valleys and bustling innovation hubs of Switzerland, Lonza Group AG has carved an indelible niche in the dynamic world of life sciences. Established in 1897, this stalwart of the biotech and pharmaceutical industry seamlessly blends traditional Swiss precision with cutting-edge scientific inquiry. Originally a chemical company, Lonza has reinvented itself over the years, today standing as a leading global provider of integrated solutions for the pharmaceutical, biotechnology, and nutrition sectors. From delivering small molecules and complex biologics to pioneering innovations in cell and gene therapy, Lonza's versatile and expansive portfolio underscores its core strength: fostering the seamless transition from early-stage research to full-scale manufacturing. This unique capability leverages a vast network of state-of-the-art facilities and expert talent, enabling Lonza to nurture groundbreaking therapies from concept through to market readiness. The secret to Lonza's business model lies in its adept mix of contract development and manufacturing (CDMO) services, enabling it to partner with a diverse clientele ranging from nimble biotechs to giant pharmaceutical firms. This breadth of collaboration adds a layer of stability and scale to its operations, generating revenue through long-term manufacturing agreements and comprehensive development programs. Lonza thrives on its ability to tailor its offerings, providing customized support at various stages of a drug’s lifecycle — from early discovery to commercial supply. Furthermore, their expansion into high-growth areas such as personalized medicine and biotechnology bolsters their competitive edge while aligning with market demand trends. This strategic alignment, coupled with a relentless pursuit of operational excellence and innovation, propels Lonza's enduring legacy as both a powerhouse and a partner in forging the future of medicine.
See Also
What is Lonza Group AG's Operating Income?
Operating Income
874m
CHF
Based on the financial report for Jun 30, 2024, Lonza Group AG's Operating Income amounts to 874m CHF.
What is Lonza Group AG's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was -39%. The average annual Operating Income growth rates for Lonza Group AG have been 13% over the past three years , 1% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
